Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Bookworm28on Aug 17, 2021 8:26pm
196 Views
Post# 33721572

RE:RE:The dynamics of the $3.2 Billion acquisition of Translate x

RE:RE:The dynamics of the $3.2 Billion acquisition of Translate x Interesting comparison.

Translate's 5 year chart is quite different from ONC's.

I had a look at the last 23 years of ONC's clinical trials: https://tinyurl.com/4rwcyczf

Not much to write home about, except for their "Carcinoma, Squamous Cell of Head and Neck" trial. This trial was very interesting/compelling. It made it to phase 3, in May of 2014 (end date). That's their only trial to make it into phase 3. That means efficacy and safety were there. Anyone know why it stalled out?

I see they intend to register for a phase 3 study after their encouraging phase 2 Aware-1 trial, but nothing concrete date-wise, yet. Anyone know the scoop on this? Thanks.

By the way, is there a difference betwen paleorep and reolysin? Looks like the same thing. Not sure why the rebrand / different name. Aren't they all the same reovirus?



<< Previous
Bullboard Posts
Next >>